CATO 佳途CATO · CNAS + ANAB ISO 17034 双体系认可标准物质生产者CNAS + ANAB ISO 17034 dual-accredited reference material producer
销售顾问Sales contact 卢振明Kaka Lu+86 185 2048 1969kaka@cato-chem.com
Rosiglitazone

罗格列酮 杂质对照品Rosiglitazone Impurities

17 个杂质条目17 impurity entries

本页汇总 罗格列酮 的 17 个杂质对照品条目。杂质谱是仿制药杂质研究、方法开发与稳定性考察的起点——先锁定品种,再逐条比对结构差异与保留行为。This page collects 17 impurity reference standards of Rosiglitazone. The impurity profile is the starting point for related-substance method development, forced degradation and stability studies.

批量索取报价 / COABulk quote / COA在全站目录中检索Search the full catalogue

相关研究文献Related literature

以下为 罗格列酮(Rosiglitazone)在公开文献中的研究报道(题录信息,来源 PubMed),供方法开发与文献调研参考。Selected peer-reviewed publications on this drug substance — bibliographic records from PubMed.

  1. 杂质研究Impurity studiesLC determination of rosiglitazone in bulk and pharmaceutical formulation
    Journal of pharmaceutical and biomedical analysis · 2002 · Radhakrishna T et al.  ·  PMID 12093521  ·  DOI
  2. 杂质研究Impurity studiesRosiglitazone, a PPAR gamma agonist: potent promoter of hydroxybutyl(butyl)nitrosamine-induced urinary bladder cancers
    International journal of cancer · 2008 · Lubet RA et al.  ·  PMID 18712722  ·  DOI
  3. 分析方法Analytical MethodsQuantification of rosiglitazone in rat plasma and tissues via LC-MS/MS: Method development, validation, and application in pharmacokinetic and tissue distribution studies
    Biomedical chromatography : BMC · 2022 · Garikapati KK et al.  ·  PMID 34993979  ·  DOI

合成路线参考Reported synthetic routes

以下为公开文献中报道的合成方法(题录信息)。标题多已点明关键反应,可据此查阅原文了解完整路线与工艺条件。Published synthetic approaches. Titles usually name the key transformation; consult the original articles for full routes.

  • 合成方法Synthesis[Rosiglitazone inhibited the transformation and synthesis of collagen in rats' embryonic lung fibroblasts through the modulation of plasminogen activator inhibitor-1]
    Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases · 2016 · Zhang Y et al.  ·  PMID 26980536  ·  DOI
  • 合成方法SynthesisRosiglitazone stimulates the release and synthesis of insulin by enhancing GLUT-2, glucokinase and BETA2/NeuroD expression
    Biochemical and biophysical research communications · 2008 · Kim HS et al.  ·  PMID 18191635  ·  DOI

罗格列酮 —— 原料药与杂质对照品Rosiglitazone — drug substance & impurities

共 18 个条目(含原料药本体)18 items incl. the drug substance
Rosiglitazone structure
原料药 APIAPI
罗格列酮Rosiglitazone
Rosiglitazone
CAS No.122320-73-4
Chemical FormulaC18H19N3O3S
Purity>95%询价On request
10mg25mg50mg100mg
N-Desmethyl Rosiglitazone-d4 structure
—
N-去甲基罗格列酮-d4N-Desmethyl Rosiglitazone-d4
N-Desmethyl Rosiglitazone-d4
CAS No.1215407-67-2
Chemical FormulaC17H13D4N3O3S
Purity>95%询价On request
5-Hydroxy Rosiglitazone-d4 structure
—
5-羟基罗格列酮-d45-Hydroxy Rosiglitazone-d4
5-Hydroxy Rosiglitazone-d4
CAS No.1246817-46-8
Chemical FormulaC18H15D4N3O4S
Purity>95%询价On request
Rosiglitazone Impurity 2 (N-Desmethyl Rosiglitazone) structure
2
罗格列酮杂质2 (N-去甲基罗格列酮)Rosiglitazone Impurity 2 (N-Desmethyl Rosiglitazone)
Rosiglitazone Impurity 2 (N-Desmethyl Rosiglitazone)
CAS No.257892-31-2
Chemical FormulaC17H17N3O3S
Purity>95%询价On request
10mg25mg50mg100mg
Rosiglitazone Impurity 4 structure
4
罗格列酮杂质4Rosiglitazone Impurity 4
Rosiglitazone Impurity 4
CAS No.643764-87-8
Chemical FormulaC14H14N2O2
Purity>95%询价On request
10mg25mg50mg100mg
Rosiglitazone Impurity 5 (Mixture of E/Z-isomers) structure
5
罗格列酮杂质5 (混合E/Z构型)Rosiglitazone Impurity 5 (Mixture of E/Z-isomers)
Rosiglitazone Impurity 5 (Mixture of E/Z-isomers)
CAS No.643764-88-9
Chemical FormulaC17H15N3O3S
Purity>95%询价On request
10mg25mg50mg100mg
Rosiglitazone Impurity 6 structure
6
罗格列酮杂质6Rosiglitazone Impurity 6
Rosiglitazone Impurity 6
CAS No.1797979-55-5
Chemical FormulaC18H23N3O2
Purity>95%询价On request
10mg25mg50mg100mg
Rosiglitazone Impurity 7 structure
7
罗格列酮杂质7Rosiglitazone Impurity 7
Rosiglitazone Impurity 7
CAS No.768-38-7
Chemical FormulaC8H12O2
Purity>95%询价On request
10mg25mg50mg100mg
Rosiglitazone Impurity 8 structure
8
罗格列酮杂质8Rosiglitazone Impurity 8
Rosiglitazone Impurity 8
CAS No.1924671-90-8
Chemical FormulaC9H14O2
Purity>95%询价On request
10mg25mg50mg100mg
Rosiglitazone Impurity 9 structure
9
罗格列酮杂质9Rosiglitazone Impurity 9
Rosiglitazone Impurity 9
CAS No.956239-35-3
Chemical FormulaC22H23N3O7S
Purity>95%询价On request
10mg25mg50mg100mg
Rosiglitazone Impurity 10 structure
10
罗格列酮杂质10Rosiglitazone Impurity 10
Rosiglitazone Impurity 10
CAS No.326496-05-3
Chemical FormulaC25H25N3O4S
Purity>95%询价On request
10mg25mg50mg100mg
Rosiglitazone Impurity 12 structure
12
罗格列酮杂质12Rosiglitazone Impurity 12
Rosiglitazone Impurity 12
CAS No.288853-59-8
Chemical FormulaC24H27N3O10S
Purity>95%询价On request
10mg25mg50mg100mg
Rosiglitazone Impurity 13 structure
13
罗格列酮杂质13Rosiglitazone Impurity 13
Rosiglitazone Impurity 13
CAS No.122321-03-3
Chemical FormulaC15H16N2O2
Purity>95%询价On request
10mg25mg50mg100mg
Rosiglitazone Impurity 14 ((5Z)-Rosiglitazone) structure
14
罗格列酮杂质14 ((5Z)-罗格列酮)Rosiglitazone Impurity 14 ((5Z)-Rosiglitazone)
Rosiglitazone Impurity 14 ((5Z)-Rosiglitazone)
CAS No.160596-25-8
Chemical FormulaC18H17N3O3S
Purity>95%询价On request
10mg25mg50mg100mg
Rosiglitazone Impurity 15 structure
15
罗格列酮杂质15Rosiglitazone Impurity 15
Rosiglitazone Impurity 15
CAS No.122320-74-5
Chemical FormulaC18H17N3O3S
Purity>95%询价On request
10mg25mg50mg100mg
Rosiglitazone Impurity 19 structure
19
罗格列酮杂质19Rosiglitazone Impurity 19
Rosiglitazone Impurity 19
CAS No.329249-53-8
Chemical FormulaC18H20N4O2S
Purity>95%询价On request
10mg25mg50mg100mg
Rosiglitazone Impurity 20 structure
20
罗格列酮杂质20Rosiglitazone Impurity 20
Rosiglitazone Impurity 20
CAS No.2247656-23-9
Chemical FormulaC15H12N4OS
Purity>95%询价On request
10mg25mg50mg100mg
Rosiglitazone Impurity 10-d4 structure
10-D4
罗格列酮杂质10-d4Rosiglitazone Impurity 10-d4
Rosiglitazone Impurity 10-d4
CAS No.1794768-28-7
Chemical FormulaC25H21D4N3O4S
Purity>95%询价On request

结构式清晰度以随货 COA 与厂家图谱为准;目录之外的杂质可按需定制合成或调取。Structural confirmation is governed by the COA and manufacturer spectra. Impurities outside this list can be custom-synthesised or sourced on request.

Literature & synthesis

罗格列酮 —— 研究文献与合成路线Rosiglitazone — literature & synthetic routes

以下题录由公开学术数据库按品种名检索汇总,供 罗格列酮 的杂质谱研究、分析方法开发与工艺路线选择参考。文献题名与专利标题均可点击查看原文,版权归原作者与出版方所有。Citations below are aggregated from public scholarly databases by drug-substance name, for reference in impurity profiling, analytical method development and route selection for Rosiglitazone. Titles link to the original records; copyright remains with the authors and publishers.

杂质与降解研究文献Impurity & degradation studies

  1. Spectrophotometric and HPLC determinations of anti-diabetic drugs, rosiglitazone maleate and metformin hydrochloride, in pure form and in pharmaceutical preparations
    Onal A · European journal of medicinal chemistry · 2009 · 被引 16cited 16
  2. LC determination of rosiglitazone in bulk and pharmaceutical formulation
    Radhakrishna T, Satyanarayana J, Satyanarayana A · Journal of pharmaceutical and biomedical analysis · 2002 · 被引 16cited 16
  3. Column high-performance liquid chromatographic method for the simultaneous determination of rosiglitazone and metformin in a pharmaceutical preparation
    Ali AR, Duraidi II, Saket MM, et al. · Journal of AOAC International · 2009 · 被引 9cited 9
  4. Anodic voltammetric behavior and determination of rosiglitazone in pharmaceutical dosage forms and biological fluids on solid electrode
    Dogan-Topal B, Tuncel S, Ozkan SA · Combinatorial chemistry & high throughput screening · 2010

合成与制备工艺专利Synthesis & process patents

  1. POLYMORPHIC FORMS OF ROSIGLITAZONE HYDROGENSULFATE AND PROCESSES FOR THEIR PREPARATION
    SEBASTIAN SONNY, SASIDHAR BALLA VENKATA, KRISHNA CHALLA, PRADHAN NITIN SHARADCHANDRA · 公开号 WO2010038154WO2010038154 · 2010
  2. PROCESS FOR PREPARATION OF INTERMEDIATES OF ROSIGLITAZONE, ROSIGLITAZONE AND POLYMORPHIC FORMS THEREOF
    LOPEZ ERNESTO DURAN · 公开号 EP2029585EP2029585 · 2009
  3. POLYMORPHIC FORMS OF ROSIGLITAZONE HYDROBROMIDE AND PROCESSES FOR THEIR PREPARATION
    KANSAL VINOD KUMAR, RANJAN HARISH, NAYAL SANJAY, RAFILOVICH MICHAL · 公开号 WO2010021745WO2010021745 · 2010
  4. Polymorphic forms of rosiglitazone hydrobromide and processes for their preparation
    KANSAL VINOD KUMAR, RANJAN HARISH, NAYAL SANJAY, RAFILOVICH MICHAL · 公开号 US2010056583US2010056583 · 2010
  5. PROCESS FOR PREPARATION OF INTERMEDIATES OF ROSIGLITAZONE, ROSIGLITAZONE AND NEW POLYMORPHIC FORMS THEREOF
    LOPEZ ERNESTO DURAN · 公开号 CA2645189CA2645189 · 2008

题录与链接来自公开数据库 Europe PMC(含 PubMed 与全球专利题录)与 WIPO PatentScope,本站仅提供索引,不转载正文;如链接失效请以数据库检索为准。Citations are indexed from public databases (Europe PMC incl. PubMed and patent records, WIPO PatentScope); we provide links only and do not reproduce full text.

For formulation & analytical R&D

罗格列酮 杂质谱研究要点Rosiglitazone — impurity profiling notes

下面这些是拿到 罗格列酮 的 18 个杂质条目之后,仿制药研发最常遇到的几件事。先把杂质的来源分清,再决定要不要买对照品、买哪几个。Once you have the 18 impurity entries for Rosiglitazone, these are the questions that come up most in generic development. Classify the source of each impurity first, then decide which reference standards you actually need.

01工艺杂质Process impurities

起始物料、中间体、副产物、催化剂与溶剂残留。多来自合成路线本身,应在工艺开发阶段用加标试验定位。Starting materials, intermediates, by-products, catalysts and residual solvents — traced back to the synthetic route and located with spiking studies during process development.

02降解杂质Degradation impurities

水解、氧化、光解、高温高湿与聚合产物。需通过强制降解试验识别,并确认方法具备稳定性指示能力。Hydrolytic, oxidative, photolytic, thermal and polymeric degradants — identified through forced degradation, with the method proven stability-indicating.

03药典杂质Pharmacopoeial impurities

EP/USP 已收载并有官方编号的杂质(如 EP Impurity A、USP Related Compound B)。申报时通常需逐项对照。Impurities already monographed with official designations (e.g. EP Impurity A, USP Related Compound B), normally compared item by item during filing.

04基因毒性杂质Genotoxic impurities

含警示结构、需按 ICH M7 进行危害评估与限度推导(TTC 1.5 µg/日)。该类杂质必须用对照品准确控制。Structurally alerting compounds requiring ICH M7 hazard assessment and limit derivation (TTC 1.5 µg/day); these must be controlled with an authentic reference standard.

05同位素标记物Isotopically labelled standards

氘代、¹³C、¹⁵N 标记的同类物,主要用作 LC-MS/MS 生物分析的内标,抵消基质效应与回收率波动。Deuterated, ¹³C- and ¹⁵N-labelled analogues used as internal standards in LC-MS/MS bioanalysis to compensate matrix effects and recovery variation.

06代谢与转化产物Metabolites & conversion products

体内代谢物、强制降解转化物与工艺中间态,常见于杂质谱比对与稳定性考察中。In-vivo metabolites, forced-degradation products and process intermediates encountered in impurity profiling and stability studies.

方法开发与对照品使用建议Method development and standards usage

先定分离,再谈定量Resolution first, then quantification

主成分与相邻杂质峰分离度应 ≥1.5;用杂质对照品确定相对保留时间与相对响应因子,避免用自身对照法掩盖响应差异。Target baseline resolution ≥1.5 between the main component and adjacent impurities; establish relative retention and relative response factors with authentic impurity standards rather than relying on self-comparison.

校正因子不可忽略Never ignore response factors

紫外吸收差异大的杂质必须校正,否则定量结果系统性偏低或偏高。EP/USP 已给出校正因子的按药典执行。Impurities with markedly different UV response need correction, otherwise results are systematically biased. Where EP/USP publish a correction factor, follow the monograph.

强制降解要做全Run the full forced-degradation panel

建议覆盖酸、碱、氧化(H₂O₂)、光照(ICH Q1B)、高温高湿;主峰纯度用二极管阵列或质谱确认。Cover acid, base, peroxide oxidation, photostability (ICH Q1B) and heat/humidity; confirm peak purity by DAD or MS.

定义报告阈值Set reporting and identification thresholds

按 ICH Q3A/Q3B 设定报告阈值、鉴定阈值与界定阈值,避免为无意义的峰投入过多工作量。Apply ICH Q3A/Q3B reporting, identification and qualification thresholds so effort is not spent on insignificant peaks.

标准品储存有讲究Store standards properly

杂质对照品多建议 −20 ℃ 避光、干燥、密封保存;溶液现配现用,并记录开瓶与配制日期。Most impurity standards should be stored at −20 °C, protected from light and moisture; prepare solutions fresh and record opening and preparation dates.

用结构式先做初判Start from the structure

先比对杂质与主成分的结构差异,可预判其保留行为、紫外响应与可能的降解路径,能显著减少试错。Comparing the impurity structure with the parent drug predicts retention behaviour, UV response and probable degradation routes, cutting trial and error.

以上为通行的杂质研究实践提示,不针对具体品种给出结论。实际限度、校正因子与色谱条件请以 EP/USP 各论及你们的验证数据为准。需要某个杂质的结构确证资料、COA 或定制合成,可直接联系我们。The above are general impurity-profiling notes and are not conclusions about this specific drug substance. Actual limits, correction factors and chromatographic conditions follow the EP/USP monograph and your own validation data. Contact us for structural confirmation data, COAs or custom synthesis.
索取杂质谱报价 / COARequest a quote / COA← 查看其它品种← Other drug substances